Trends Immunol. 2026 Jul 2:S1471-4906(26)00162-6. doi: 10.1016/j.it.2026.06.006. Online ahead of print.
ABSTRACT
Interleukin-33 (IL-33) is classically viewed as an alarmin, but in cancer, it may do more than merely initiate immunity. I propose that IL-33 scripts the trajectory of immunity through interconnected regulatory layers that influence how host responses are organized and ultimately resolved into either productive antitumor immunity or suppressive, repair-like states.
PMID:42392913 | DOI:10.1016/j.it.2026.06.006